Clinical Trial

Study of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLC

Study acronym: TianjinCIH
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, open, single-center, single-arm phase II clinical study in non-small cell lung cancer (NSCLC) without common EGFR-sensitive mutations (Ex19del and L858R) or ALK fusion variants identified in the central laboratory. To evaluate the efficacy and safety of neoadjuvant therapy of sacituzumab tirumotecan combined with toripalimab.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-02-22; most recent amendment 2026-03-23.
Trial Details
NCT Number NCT07438600
Lead Sponsor Tianjin Medical University Cancer Institute and Hospital
Conditions NSCLC (Non-small Cell Lung Cancer)
Enrollment 38 participants
Start Date 2026-02-24
Primary Completion 2027-02-28 (estimated)
Study Completion 2028-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-03-27